Cambrian BioPharma, Inc. Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2019

Location

New York NY US

Primary Industry

Biotechnology

About

Based in New York, US, and founded in 2019 by its CEO, James Peyer, and founders Christian Angermayer and Sebastian Brunemeier, Cambrian BioPharma, Inc. is a distributed drug discovery company that collaborates with leading research institutions and start-ups, offering funding and resources to advance a portfolio of drug discovery projects with a common theme. As of 2021, Cambrian has 14 new drugs in progress across its portfolio of businesses. The company raised USD 60 million in funding in February 2021. In October 2021, Cambrian BioPharma, Inc. raised USD 100 million in series C funding co-led by Anthos Capital and Salt Ventures, with Apeiron Investment Group, Future Ventures, and Moore Capital Management. The Cambrian BioPharma platform advances treatments and medications to reduce and treat age-related illnesses such as heart disease, cancer, and dementia, allowing scientists to transfer findings from the lab to the clinic and deliver medicines to patients in need. Cambrian BioPharma will use the series C funding to continue advancing its existing pipeline and partner with additional scientific innovators to bring more programs under the Cambrian banner.

Current Investors

FJ Labs, NJF Capital, Future Ventures

Request a demo to show more

Primary Industry

Biotechnology

Sub Industries

Bioinformatics, Pharmaceutical Research & Development

Website

www.cambrianbio.com

Company Stage

Series C

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.